Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Nov;17(11):824-8.
doi: 10.3779/j.issn.1009-3419.2014.11.09.

[Research progress of targeted therapy in non-small cell lung cancer brain metastases]

[Article in Chinese]
Tao Jiang  1 , Caicun Zhou  1
Affiliations
Review

[Research progress of targeted therapy in non-small cell lung cancer brain metastases]

[Article in Chinese]
Tao Jiang et al. Zhongguo Fei Ai Za Zhi. 2014 Nov.

Abstract
in English, Chinese

Lung cancer is characterized by the highest incidence of solid tumor-related brain metastases, which are reported the incidence ranged 20% to 65%. This is also one of the reasons why it can cause significant mortality. Molecular targeted therapy plays a major role in the management of brain metastases in lung cancer. Targeted agents have become the novel methods for the treatment of lung cancer with brain metastases beyond the whole brain radiation therapy, stereotactic radiosurgery and chemotherapy. Recently, more and more studies and trials laid emphasis on the targeted agents for non-small cell lung cancer (NSCLC) brain metastases treatment. The key point is the efficacy and safety. In this paper, the targeted treatments of NSCLC brain metastases were summarized.

肺癌最常见的远处转移部位之一是脑部，肺癌脑转移的发生率为20%-65%，是脑转移性肿瘤中最常见的类型，同时也是肺癌死亡率高居不下的原因之一。分子靶向治疗已成为肺癌治疗的重要手段，分子靶向药物也成为继全脑放疗、立体定向放疗和化疗之后肺癌脑转移新的治疗方法。目前，对脑转移的非小细胞肺癌患者应用靶向药物治疗的研究也越来越多，其安全性和有效性是研究的重点。本文就靶向药物治疗非小细胞肺癌脑转移的研究进展做一综述。

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Preusser M, Capper D, Ilhan-Mutlu A, et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol. 2012;123(2):205–222. doi: 10.1007/s00401-011-0933-9. - DOI - PubMed
    1. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865–2772. doi: 10.1200/JCO.2004.12.149. - DOI - PubMed
    1. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48–54. doi: 10.1007/s11912-011-0203-y. - DOI - PubMed
    1. Socinski MA, Evans T, Gettinger S, et al. Treatment of stage Ⅳ non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e341S–e368S. doi: 10.1378/chest.12-2361. - DOI - PMC - PubMed
    1. Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419–425. doi: 10.1200/JCO.2011.38.0527. - DOI - PMC - PubMed

MeSH terms

Substances